ZOM Stock Overview A veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add noteZomedica Corp. Competitors Price History & Performance
Summary of share price highs, lows and changes for Zomedica Historical stock prices Current Share Price US$0.13 52 Week High US$0.23 52 Week Low US$0.12 Beta 1.06 1 Month Change -3.24% 3 Month Change -1.80% 1 Year Change -42.42% 3 Year Change -64.20% 5 Year Change -61.71% Change since IPO -84.89%
Recent News & Updates Zomedica Appoints Scott A. Jordan as Executive Vice President, Effective January 1, 2025
Senior Vice President of Sales recently bought US$60k worth of stock Nov 14
Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform Nov 14
Third quarter 2024 earnings released: US$0.007 loss per share (vs US$0.001 loss in 3Q 2023) Nov 10
Zomedica Corp. Launches Ear Cytology Quick Scan Protocol for TRUVIEW Digital Microscope & Telepathology Platform Oct 25
Zomedica Corp. to Report Q3, 2024 Results on Nov 07, 2024 Oct 24 See more updates Zomedica Appoints Scott A. Jordan as Executive Vice President, Effective January 1, 2025
Senior Vice President of Sales recently bought US$60k worth of stock Nov 14
Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform Nov 14
Third quarter 2024 earnings released: US$0.007 loss per share (vs US$0.001 loss in 3Q 2023) Nov 10
Zomedica Corp. Launches Ear Cytology Quick Scan Protocol for TRUVIEW Digital Microscope & Telepathology Platform Oct 25
Zomedica Corp. to Report Q3, 2024 Results on Nov 07, 2024 Oct 24
Zomedica's Assisi Loop Product Line Designated as Fear Free(TM) Preferred Product Aug 29
Zomedica Corp. Introduces Enhanced Audio Features for the Vetguardian Zero-Touch Vital Signs Remote Monitoring System Aug 22
Second quarter 2024 earnings released: US$0.024 loss per share (vs US$0.005 loss in 2Q 2023) Aug 16 Zomedica Corp. Reiterates Financial Guidance for Full Year 2024
Zomedica Corp. Expands Truforma Addressable Market with Launch of Equine Cortisol Assay for the Platform Jun 28
Senior Vice President of Sales recently bought US$105k worth of stock Jun 13
Zomedica Corp. Releases Over-The-Air Software Update Capabilities for Its Truforma(R) Platform May 16
Zomedica Corp. Provides Revenue Guidance for Full Year 2024 May 11
New minor risk - Share price stability May 11
First quarter 2024 earnings released: US$0.009 loss per share (vs US$0.007 loss in 1Q 2023) May 10
Zomedica Corp. to Report Q1, 2024 Results on May 09, 2024 May 01
Zomedica Corp., Annual General Meeting, Jun 06, 2024 Apr 13
Zomedica Corp. Provides Revenue Guidance for Full Year 2024 Apr 03
Full year 2023 earnings released: US$0.035 loss per share (vs US$0.017 loss in FY 2022) Apr 02
Zomedica Corp. to Report Q4, 2023 Results on Apr 01, 2024 Mar 21 Zomedica Corp. Announces Publication of Research Con Including TRUFORMA(R) Platform Is More Accurate Diagnostic Test for Feline Hyperthyroidism Than Chemiluminescent Immunoassay (CLIA) Platform
New minor risk - Share price stability Jan 22
Zomedica Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Full Year 2024 Jan 18
Zomedica Corp. Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease Dec 18
Zomedica Announces Presentation of Clinical Data in Support of New Indications for Pulsevet Shock Wave Therapy Dec 06
Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.005 loss in 3Q 2022) Nov 16
Zomedica Corp. to Report Q3, 2023 Results on Nov 13, 2023 Nov 03 Zomedica Corp. (NYSEAM:ZOM) acquired Qorvo Biotechnologies, LLC from Qorvo US, Inc. Oct 06
Zomedica Corp. Launches its Newest Assay - Endogenous ACTH Sep 15
Zomedica Receives Non-Compliance Notice from NYSE American Sep 14
Second quarter 2023 earnings released: US$0.005 loss per share (vs US$0.005 loss in 2Q 2022) Aug 11
High number of new directors Jul 01
New major risk - Revenue and earnings growth Jun 20
Zomedica Corp. Launches Revolutionary TRUVIEW(TM) Digital Microscope with Advanced Optics, Automated Slide Preparation, and Telepathology Services Jun 10
First quarter 2023 earnings released: US$0.007 loss per share (vs US$0.004 loss in 1Q 2022) May 13
Full year 2022 earnings released: US$0.017 loss per share (vs US$0.053 loss in FY 2021) Mar 17 Zomedica Corp. to Report Q4, 2022 Results on Mar 15, 2023
Third quarter 2022 earnings released: US$0.005 loss per share (vs US$0.006 loss in 3Q 2021) Nov 16
Zomedica Corp. to Report Q3, 2022 Results on Nov 14, 2022 Nov 03
Zomedica Corp. Announces Launch of Free T4 Assay for Truforma(R) Diagnostic Platform Sep 14
Zomedica Corp. Appoints Pamela Nichols to Board of Directors and Audit and Governance Committees Aug 24
Second quarter 2022 earnings released: US$0.005 loss per share (vs US$0.005 loss in 2Q 2021) Aug 16
Zomedica Corp. (NYSEAM:ZOM) acquired Substantially All the Assets of Assisi Animal Health, LLC. Jul 19 Zomedica Corp. Announces Management Changes
First quarter 2022 earnings released: US$0.004 loss per share (vs US$0.041 loss in 1Q 2021) May 12
Zomedica Corp. Signs TRUFORMA Distribution Agreement with Miller Veterinary Supply Jan 26
Zomedica Corp. Appoints Robert Cohen as Chief Executive Officer Jan 05
Zomedica Corp. Appoints Ann Marie Cotter as Chief Financial Officer Oct 07
Zomedica Pharmaceuticals Corp. Approves Board Appointments Sep 26
Zomedica Pharmaceuticals Corp. has completed a Follow-on Equity Offering in the amount of $29.9975 million. Jul 08 Shareholder Returns ZOM US Medical Equipment US Market 7D 1.9% -1.5% -2.4% 1Y -42.4% 10.0% 23.4%
See full shareholder returns
Return vs Market: ZOM underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is ZOM's price volatile compared to industry and market? ZOM volatility ZOM Average Weekly Movement 7.0% Medical Equipment Industry Average Movement 7.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ZOM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ZOM's weekly volatility (7%) has been stable over the past year.
About the Company Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy.
Show more Zomedica Corp. Fundamentals Summary How do Zomedica's earnings and revenue compare to its market cap? ZOM fundamental statistics Market cap US$122.79m Earnings (TTM ) -US$62.19m Revenue (TTM ) US$26.73m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ZOM income statement (TTM ) Revenue US$26.73m Cost of Revenue US$8.12m Gross Profit US$18.61m Other Expenses US$80.81m Earnings -US$62.19m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.063 Gross Margin 69.64% Net Profit Margin -232.70% Debt/Equity Ratio 0%
How did ZOM perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 02:28 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Zomedica Corp. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Swayampakula Ramakanth H.C. Wainwright & Co. Robert LeBoyer NOBLE Capital Markets, Inc.
Show 0 more analysts